ABA 101
Alternative Names: ABA-101Latest Information Update: 14 Oct 2024
Price :
$50 *
At a glance
- Originator Abata Therapeutics
- Class Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Multiple sclerosis
Most Recent Events
- 24 Sep 2024 Phase-I clinical trials in Multiple sclerosis in USA (Parenteral) (NCT06566261)
- 23 Aug 2024 Abata Therapeutics plans a phase I trial for Multiple sclerosis in September 2024 (Parenteral) (NCT06566261)
- 22 Aug 2024 ABA 101 receives Fast Track designation for Multiple sclerosis [Parenteral] in USA